Effects of Patient Preferences on Outcomes in the Predictors of Remission in Depression to Individual and Combined Treatments (PReDICT) Study

• DOI: 10.1176/appi.ajp.2016.16050517
• Publication Date: 2017-03-24T12:20:54Z
• Authors: Boadie W. Dunlop; Mary E. Kelley; Vivianne Aponte-R...; Tanja Mletzko-Crowe; Becky Kinkead; James C. Ritchie; Charles B. Nemeroff; W. Edward Craighead; Helen S. Mayberg
• Keywords: Depression

The Predictors of Remission in Depression to Individual and Combined Treatments [PReDICT] study aimed identify clinical biological factors predictive treatment outcomes major depressive disorder among treatment-naive adults. authors evaluated the efficacy cognitive-behavioral therapy (CBT) two antidepressant medications (escitalopram duloxetine) patients with depression examined moderating effect patients' preferences on outcomes.Adults aged 18-65 were randomly assigned equal likelihood 12 weeks escitalopram (10-20 mg/day), duloxetine (30-60 or CBT (16 50-minute sessions). Prior randomization, indicated whether they preferred medication had no preference. primary outcome was change 17-item Hamilton Rating Scale (HAM-D), administered by raters blinded treatment.A total 344 assigned, a mean baseline HAM-D score 19.8 (SD=3.8). estimated overall decreases did not significantly differ between treatments (CBT: 10.2, escitalopram: 11.1, duloxetine: 11.2). Last observation carried forward remission rates 41.9%, 46.7%, 54.7%). Patients matched their more likely complete trial but achieve remission.Treatment guidelines that recommend either an evidence-based psychotherapy for nonpsychotic can be extended patients. Treatment without prior exposure do moderate symptomatic outcomes.